**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 78884

**Manuscript Type:** MINIREVIEWS

**Ketosis-prone diabetes mellitus: A phenotype that hospitalists need to understand**

Boike S *et al*. Ketosis prone diabetes

Sydney Boike, Mikael Mir, Ibtisam Rauf, Abbas B Jama, Shaleen Sunesara, Hisham Mushtaq, Anwar Khedr, Jain Nitesh, Salim Surani, Syed A Khan

**Sydney Boike, Mikael Mir,** Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, United States

**Ibtisam Rauf,** Medicine, St. George’s School of Medicine, Grenada FZ818, West Indies

**Abbas B Jama, Jain Nitesh, Syed A Khan,** Critical Care Medicine, Mayo Clinic Health System, Mankato, MN 56001, United States

**Shaleen Sunesara,** Medicine, University of Southern California, Los Angeles, CA 90007, United States

**Hisham Mushtaq,** Medicine, St. Vincent’s Medical Center, Bridgeport, CT 06606, United States

**Anwar Khedr,** Medicine, BronxCare Health System, Bronx, NY 10457, United States

**Salim Surani,** Medicine, Texas A&M University, Bryan, TX 77843, United States

**Salim Surani,** Anesthesiology, Mayo Clinic, Rochester, MN 55905, United States

**Author contributions:** Boike S, Mir M, Rauf I, and Jama AB contributed to conceptualization, drafting, reviewing, final editing, and agreeing to the accuracy of the work; Mushtaq H, Khedr A, and Nitesh J contributed to literature search and review of the manuscript; Surani S and Khan SA contributed to supervision, critical revision of the manuscript, editing, reviewing, and agreeing to the final accuracy of the work.

**Corresponding author: Salim Surani, FCCP, MD, MS, Professor,** Medicine, Texas A&M University, College Station, Bryan, TX 77843, United States. srsurani@hotmail.com

**Received:** July 20, 2022

**Revised:** August 23, 2022

**Accepted:** September 9, 2022

**Published online:** October 26, 2022

**Abstract**

Diabetes has been classified mainly into types 1 and 2. Some type 2 diabetes patients, when developing ketosis, have been labeled as having atypical diabetes. Lately, syndromes of ketosis-prone diabetes, primarily in patients who we previously classified as type 2 diabetics, have emerged, and calls are being made to even reclassify diabetes. This mini-review will extensively deal with the historical, molecular, phenotypical, and clinical basis of why ketosis-prone diabetes is different than the traditional principles of type 1 and 2 diabetes and should be classified as such. Clinicians, especially those who are not diabetologists or endocrinologists, as well as hospitalists, intensivists, and primary care providers, will greatly benefit from this review.

**Key Words:** Diabetic ketoacidosis; Diabetes; Diabetes prone ketosis; Ketosis; Acidosis

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Boike S, Mir M, Rauf I, Jama AB, Sunesara S, Mushtaq H, Khedr A, Nitesh J, Surani S, Khan SA. Ketosis-prone diabetes mellitus: A phenotype that hospitalists need to understand. *World J Clin Cases* 2022; 10(30): 10867-10872

**URL:** https://www.wjgnet.com/2307-8960/full/v10/i30/10867.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i30.10867

**Core Tip:** Diabetes is one of the most common chronic diseases globally. Ketosis-prone diabetes is now being increasingly recognized. The majority of patients with ketosis-prone diabetes are being diagnosed at the time of their presentation as diabetic ketoacidosis. Its presentation is unique, and it has components of both type 1 and type 2 diabetes. This article helps the clinician understand the pathophysiology of this phenotype.

**INTRODUCTION**

The earliest record of diabetes was described on the Ebers Papyrus. An Egyptian document is believed to be from approximately 1500 before Christ (BC)[1]. At present, diabetes is estimated to affect over 420 million people worldwide, with expectations that this number will rise to over 500 million by the end of this decade. According to the Report of the global Diabetes Summit, co-hosted by the World Health Organization and the Government of Canada[2-4].

Diabetes is broadly categorized as diabetes mellitus, diabetes insipidus, and gestational diabetes, with diabetes mellitus and diabetes insipidus having further subcategorizations of type 1 and type 2. Gestational diabetes is defined as glucose intolerance that is first discovered during pregnancy. It affects 2%-5% of pregnant women and risk factors include a strong family history of diabetes and obesity. Diabetic ketoacidosis (DKA) can develop as a life-threatening complication for both the mother and the fetus. The incidence of occurrence of DKA ranges from 0.5%-10.0% in gestational diabetes. Its pathophysiology can be characterized by insulin resistance and respiratory alkalosis. Considered a physiologic mechanism to preserve glucose for the fetus, insulin sensitivity for the mother is decreased. Furthermore, increased alveolar ventilation in the mother results in respiratory alkalosis that is offset by increased bicarbonate secretion which can lead to ketoacidosis. Additionally, the fetus uses a significant amount of maternal glucose, which leads to decreased fasting glucose of the mother, which in relation to the insulin deficiency leads to increased production of free fatty acids that are converted to ketones in the liver[5].

Different forms of diabetes have been increasingly recognized in the last few decades. Some published work includes the characterization of ketosis-prone diabetes (KPD), also called ketosis-prone type 2 diabetes mellitus (KPDM), Flatbush diabetes, idiopathic type 1 diabetes, or atypical diabetes[6,7]. KPD is unique in that its presentation and the clinical course contain elements of both types 1 and 2 diabetes mellitus[6].

Here we aim to review the contemporary literature and outline the background, molecular, phenotype, and clinical basis of why this ketosis-prone diabetes is different and must be classified as so to benefit clinicians. This review provides the current understanding of KPD with recent literature and can serve as a resource for medical professionals during their clinical decision-making.

**Background and history of KPD**

KPD, commonly known as “Flatbush Diabetes”, refers to a hybrid form of diabetes that has various characteristics of type 1 diabetes and type 2 diabetes[8]. Type 1 diabetes is caused by the autoimmune loss of insulin-producing beta cells in the pancreas. Patients become dependent on insulin as a result of this, and the lack of natural insulin makes patients vulnerable to DKA. On the other hand, type 2 diabetes differs from type 1 diabetes because it is caused by insulin resistance in the body in elderly patients, which leads to beta-cell burnout over time[5].KPD is a type 2 diabetes-like illness that involves DKA but occurs later in life and can regain beta cell activity, similar to type 2 diabetes. KPD has similar biochemical and acid-base parameters to type 1 diabetes[5].

KPD has been recognized as a medical condition since 1984. Most of the early studies were focused on African American individuals but have shifted to sub-Saharan African, Hispanic, and Asian populations in recent years. Studies show that Blacks and Hispanics account for 20%-50% of KPD patients in the United States[8]. KPD predominantly affects African American men who are overweight, have a family history of KPD, and have a low prevalence of autoimmune markers[8].

KPD is believed to commence with ketoacidosis in people who lack autoimmune markers, islet cell antibodies, and glutamic acid decarboxylase (GAD) autoantibodies[9].People dealing with these conditions require insulin replacement, but it may be possible for them to end insulin treatment in the future, depending on the progress of treatment and the condition of the individual. This unusual condition that does not fit traditional categories is described as KPD[9]. Furthermore, at the initial stage of diagnosis, many individuals will have impaired insulin secretion in addition to complications such as ketosis or DKA[10]. Studies have found that up to 75% of people who have KPD had DKA at the diagnosis level. The classification of KPD is dependent on testing for GAD, anti-islet cell antibodies, and fasting C-peptide levels[8].

**Pathophysiology**

KPD departs from the classical presentations of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Whereas T1DM is the autoimmune destruction of pancreatic B-cells, and T2DM is characterized by insulin resistance and B-cell dysfunction, KPD has unique pathogenesis. It lacks the immunologic markers to distinguish it as T1DM but also lacks the insulin requirements to be considered T2DM. Considered the third type of diabetes, there are four classifications for KPD: The American Diabetes Association (ADA) classification, the modified ADA system, the BMI system, and the Aß system[11]. The Aß system distinguishes four subgroups based on the presence/absence of autoantibodies and ß cell function. The four subgroups include autoantibodies present beta-cell function absent (A+ß-), autoantibodies present beta-cell function present (A+ß+), autoantibodies absent beta-cell function absent (A-ß-), and autoantibodies absent beta-cell function present (A-ß+) (Table 1).

Differentiating A+ß- from A+ß+ KPD allows exploration into autoimmune pathways that lead to distinct patterns of beta-cell loss. The more moderate clinical course of A+ß+ KPD patients compared with A+ß- KPD patients may be related in part to epitope-specific antibodies to the 65-kDa isoform of glutamic acid decarboxylase (GAD65)[12]. Furthermore, a specific amino-terminal epitope defined by monoclonal antibody DPD is correlated with a higher beta-cell functional reserve and was associated with the milder A+ß+[13]. However, the mechanisms that create the autoantibody specificity and result in variable beta-cell functional reserve remains to be known. In healthy individuals, GAD65 antibodies (GAD65Ab) are present in the sera but are masked by anti-idiotypic antibodies[13]. Masked GAD65Ab specific for the epitope DPD is strongly associated with preserved beta-cell function among patients with KPD[13]. Additionally, circulating insulin DNA is a biomarker for A+ß+ KPD patients, though absent in A+ß- KPD patients[14].

A-ß- KPD is characterized by beta cell failure and undetectable autoimmunity. Some A-ß- KPD patients may be misclassified as “A-” because of a decline in autoantibody titers over time though a decline in antibody titer is less likely as GAD autoantibodies are reportedly durable[11]. Most A-ß- KPD patients have relatives with a strong family history of diabetes, which suggests a familial trait and defects in genes responsible for beta-cell development and function[15]. Significant variants in the genes encoding the key beta-cell transcription factors hepatocyte nuclear factor-1-alpha (HNF1a), PAX-4, pancreas-duodenum homeobox-1 (PDX-1), TCF1, PAX-4, PDX-1, are enhanced in A-ß- KPD which may contribute to a monogenic etiology for some patients with the A-ß- phenotype[15].

Finally, the A-ß+ phenotype is characterized by partially reversible beta-cell dysfunction, which may be due to metabolic, genetic, or viral etiologies[16]. Dysfunctional pathways of branch chain amino acid (BCAA) and arginine/citrulline metabolism in A-ß+ patients were discovered by a plasma metabolomics survey[10].A-ß+ patients had impaired ketone oxidation and fatty acid oxidation, resulting in increased leucine catabolism which highlights an aberrant mechanism for energy production and ketosis in A-ß+ KPD[10]. It was also found that A-ß+ patients in acute episodes of DKA had impaired catabolism and accelerated fatty acid conversion of ketones, similar to the T1DM patients[17].

**Clinical presentation**

The clinical presentation of KPD follows a similar constellation of symptoms across those affected. The majority affected are considered to be of middle age, are classified as obese, and have recently received a diagnosis of diabetes mellitus[18].These individuals present abruptly with DKA and classically follow a similar history prior to presentation (increased urination, increased thirst, and associated weight loss), with a predilection of men *vs* women being affected by the condition[18]. Of those who present with KPD, they classically do not have the standard phenotypic expression of autoimmune type I diabetes, which is what one may expect in a patient presenting with DKA. That is, many present with features similar to type 2 diabetes, including the previously listed symptoms of obesity and diagnosis of diabetes in middle age, in addition to strong family history, hypertension, and beta-cell functional reserve[19]. Regarding findings obtained in labs, these individuals present with severe hyperglycemia, ketosis +/- acidosis, and will commonly have negative panels for autoantibodies against beta-cell antigens[20], further distinguishing this pathology from type 1 or type 2 diabetes mellitus. Certain ethnicities are more commonly associated with KPD as well. In a 2004 study performed by Maldonado *et al*[21], 321 patients were interviewed over a span of 3.5 years, in which information was collected to analyze group differences. They found that 44% of individuals were African American, 40% were Hispanic, and 16% were Caucasian.

Finally, the course of this pathology can follow a similar timeline of events. In a review performed in 2006 by Umpierrez *et al*[18], they collected data from biomedical literature from 1966-2005 and concluded that individuals with KPD who present with an acute error of insulin production will usually have near-resolution of symptoms within several weeks of insulin treatment and later will progress to a nearly normoglycemic state that can last for months to years. This unique presentation and course of events further help to distinguish this subtype of diabetes from others and can help tailor the approach to treatment for patients.

Several studies have found that coronavirus disease 2019 (COVID-19) infection triggers the onset of KPD, but the exact mechanism is still unknown. Further investigation is needed to understand the distinct relationship between COVID-19 and KPD. A possible theory is that COVID-19 infection triggers changes in the human body that result in insulin resistance or cause pancreatic beta cells to be destroyed. Another possibility is that antibodies against COVID-19 can affect the role of endogenous insulin in the body[22].

**Clinical management of KPD**

Management of KPD is divided into three stages: acute management of DKA, evaluation of the KPD subgroup after DKA resolution, and long-term health maintenance. KPD patients who present with DKA should be managed according to standard care methods for DKA, regardless of subtype. These inpatient protocols include aggressive fluid replacement to restore circulatory volume, regular IV insulin therapy, evaluation and treatment of precipitating factors, correcting the hyperglycemia, stabilizing the electrolyte disorders, and alleviating ketoacidosis[23]. This treatment plan should be followed with a transition from IV insulin therapy to subcutaneous regimens[23].Additionally, all KPD patients should be given a discharge plan that provides 24-h insulin coverage. Insulin may be discontinued only after a thorough evaluation and accurate classification of the KPD subtype and assessing the patient’s predictive factors. This evaluation should be performed at the first outpatient visit following discharge from the hospital, preferably after 1-3 wk.

Evaluation of the KPD subgroup is performed *via* assessment of beta-cell secretory reserve and beta-cell immunology (Table 1). This evaluation is usually performed at least 1-3 wk after the resolution of DKA to minimize the effects of glucose toxicity and beta-cell desensitization on the diagnostic parameters. The beta-cell secretory reserve is measured with C-peptide levels during a fasted state or after glucagon stimulation, and it is a strong predictor of long-term glycemic control[24] and insulin discontinuation[25]. Patients are classified as ß+ if they have adequate beta-cell reserve with a fasting serum C-peptide concentration greater than or equal to 1 ng/mL (0.33 nmol/L) or a peak serum C-peptide response to glucagon greater than or equal to 1.5 ng/mL (0.5 nmol/L)[11]. Patients are classified as ß- if they have inadequate beta-cell reserve with a fasting serum C-peptide concentration is less than 1 ng/mL (0.33 nmol/L) or a peak serum C-peptide response to glucagon less than 1.5 ng/mL (0.5 nmol/L)[11]. This classification scheme is used due to its high accuracy and predictive value[26]. Quantitative assessment of beta-cell auto-antibodies is also valuable for this clinical evaluation, especially in patients with the A+ß+ KPD phenotype. The serum autoantibodies measured include anti-glutamic acid decarboxylase (GAD65) and anti-islet tyrosine phosphatase 2 (IA-2), and increased accuracy of this classification is also often done by measuring serum titers of autoantibodies to the zinc transporter 8 (ZnT8) antigen[11]. Patients are then classified as A+ or A- based on the presence of a significant number of autoantibodies.

Once the patient has been classified with a KPD subtype, began on appropriate therapy, and been assessed for risk factors for subsequent ketotic episodes, the standard protocol for diabetes management should be followed for long-term management of KPD. In addition to other forms of diabetes mellitus, all subtypes of KPD should be managed with lifestyle changes, including appropriate diet and adequate exercise. A registered dietician is recommended, along with a diabetic educator as needed. Additional measures include weight loss in obese patients, smoking cessation, if applicable, and physical activity multiple times a week[27].Insulin discontinuation in ß+ can be achieved by evaluating for factors such as new diagnosis of diabetes, older age at onset, and high beta-cell secretary reserve. The presence of beta-cell autoantibodies can also be used to determine beta-cell function in the future and insulin discontinuation. Although KPD patients with autoantibodies tend to have a lower beta-cell function at the time of diagnosis and at follow-up, approximately 50% of A+ß+ KPD patients maintain a long-term beta-cell secretory reserve[28]. Due to the unpredictability of beta-cell reserve, A+ß+ KPD patients can also come off insulin therapy initially but require close monitoring for at least two years. HLA subtyping is useful in predicting long-term outcomes because it can elucidate those patients who will most likely have a more severe experience.

**CONCLUSION**

Syndromes of ketosis-prone diabetes have been described in the literature, and much has been learned about the condition. However, much is still unknown about the etiology, treatment, and why it affects certain ethnicities more than others. The wide range of presentations and classifications poses an obstacle to proper preventative and clinical management of KPD since the pathophysiology of each subtype is different. The role of genetics and genotyping in KPD has yet to be elucidated, but further understanding of both the etiology and risk factors of KPD will guide clinicians in determining the most effective therapies for the management of the condition and the prevention of ketosis.

**REFERENCES**

1 **King KM**, Rubin G. A history of diabetes: from antiquity to discovering insulin. *Br J Nurs* 2003; **12**: 1091-1095 [PMID: 14581842 DOI: 10.12968/bjon.2003.12.18.11775]

2 **World Health Organization**. Improving diabetes outcomes for all, a hundred years on from the discovery of insulin. [cited 18 July 2022]. Available from: https://www.who.int/publications-detail-redirect/9789240038943

3 **World Health Organization**. Diabetes. [cited 18 July 2022]. Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes

4 **Balasubramanyam A**, Nalini R, Hampe CS, Maldonado M. Syndromes of ketosis-prone diabetes mellitus. *Endocr Rev* 2008; **29**: 292-302 [PMID: 18292467 DOI: 10.1210/er.2007-0026]

5 **Eshkoli T**, Barski L, Faingelernt Y, Jotkowitz A, Finkel-Oron A, Schwarzfuchs D. Diabetic ketoacidosis in pregnancy - Case series, pathophysiology, and review of the literature. *Eur J Obstet Gynecol Reprod Biol* 2022; **269**: 41-46 [PMID: 34968873 DOI: 10.1016/j.ejogrb.2021.12.011]

6 **Vellanki P**, Umpierrez GE. DIABETIC KETOACIDOSIS: A COMMON DEBUT OF DIABETES AMONG AFRICAN AMERICANS WITH TYPE 2 DIABETES. *Endocr Pract* 2017; **23**: 971-978 [PMID: 28534682 DOI: 10.4158/EP161679.RA]

7 **Álvarez-Aldana D**. Improving Ketosis-Prone Type 2 Diabetes Diagnosis in Africa. *MEDICC Rev* 2021; **23**: 61-62 [PMID: 34516538 DOI: 10.37757/MR2021.V23.N3.11]

8 **Lebovitz HE**, Banerji MA. Ketosis-Prone Diabetes (Flatbush Diabetes): an Emerging Worldwide Clinically Important Entity. *Curr Diab Rep* 2018; **18**: 120 [PMID: 30280274 DOI: 10.1007/s11892-018-1075-4]

9 **Safder SB**, Mortada R. Diabetes 1.5: Ketone-Prone Diabetes. *Clin Diabetes* 2015; **33**: 150-151 [PMID: 26203209 DOI: 10.2337/diaclin.33.3.150]

10 **Patel SG**, Hsu JW, Jahoor F, Coraza I, Bain JR, Stevens RD, Iyer D, Nalini R, Ozer K, Hampe CS, Newgard CB, Balasubramanyam A. Pathogenesis of A⁻β⁺ ketosis-prone diabetes. *Diabetes* 2013; **62**: 912-922 [PMID: 23160531 DOI: 10.2337/db12-0624]

11 **Maldonado M**, Hampe CS, Gaur LK, D’Amico S, Iyer D, Hammerle LP, Bolgiano D, Rodriguez L, Rajan A, Lernmark A, Balasubramanyam A. Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and beta-cell functional classification, prospective analysis, and clinical outcomes. *J Clin Endocrinol Metab* 2003; **88**: 5090-5098 [PMID: 14602731 DOI: 10.1210/jc.2003-030180]

12 **Hampe CS**, Nalini R, Maldonado MR, Hall TR, Garza G, Iyer D, Balasubramanyam A. Association of amino-terminal-specific antiglutamate decarboxylase (GAD65) autoantibodies with beta-cell functional reserve and a milder clinical phenotype in patients with GAD65 antibodies and ketosis-prone diabetes mellitus. *J Clin Endocrinol Metab* 2007; **92**: 462-467 [PMID: 17090641 DOI: 10.1210/jc.2006-1719]

13 **Oak S**, Gaur LK, Radtke J, Patel R, Iyer D, Ram N, Gaba R, Balasubramanyam A, Hampe CS. Masked and overt autoantibodies specific to the DPD epitope of 65-kDa glutamate decarboxylase (GAD65-DPD) are associated with preserved β-cell functional reserve in ketosis-prone diabetes. *J Clin Endocrinol Metab* 2014; **99**: E1040-E1044 [PMID: 24601691 DOI: 10.1210/jc.2013-4189]

14 **Mulukutla SN**, Tersey SA, Hampe CS, Mirmira RG, Balasubramanyam A. Elevated unmethylated and methylated insulin DNA are unique markers of A+β+ ketosis prone diabetes. *J Diabetes Complications* 2018; **32**: 193-195 [PMID: 29175121 DOI: 10.1016/j.jdiacomp.2017.10.013]

15 **Haaland WC**, Scaduto DI, Maldonado MR, Mansouri DL, Nalini R, Iyer D, Patel S, Guthikonda A, Hampe CS, Balasubramanyam A, Metzker ML. A-beta-subtype of ketosis-prone diabetes is not predominantly a monogenic diabetic syndrome. *Diabetes Care* 2009; **32**: 873-877 [PMID: 19228875 DOI: 10.2337/dc08-1529]

16 **Umpierrez GE**, Smiley D, Gosmanov A, Thomason D. Ketosis-prone type 2 diabetes: effect of hyperglycemia on beta-cell function and skeletal muscle insulin signaling. *Endocr Pract* 2007; **13**: 283-290 [PMID: 17599861 DOI: 10.4158/EP.13.3.283]

17 **Jahoor F**, Hsu JW, Mehta PB, Keene KR, Gaba R, Mulukutla SN, Caducoy E, Peacock WF, Patel SG, Bennet R, Lernmark A, Balasubramanyam A. Metabolomics Profiling of Patients With A-β+ Ketosis-Prone Diabetes During Diabetic Ketoacidosis. *Diabetes* 2021; **70**: 1898-1909 [PMID: 34021044 DOI: 10.2337/db21-0066]

18 **Umpierrez GE**, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. *Ann Intern Med* 2006; **144**: 350-357 [PMID: 16520476 DOI: 10.7326/0003-4819-144-5-200603070-00011]

19 **Otiniano ME**, Balasubramanyam A, Maldonado M. Presence of the metabolic syndrome distinguishes patients with ketosis-prone diabetes who have a Type 2 diabetic phenotype. *J Diabetes Complications* 2005; **19**: 313-318 [PMID: 16260347 DOI: 10.1016/j.jdiacomp.2005.03.001]

20 **Sjöholm Å**. Ketosis-Prone Type 2 Diabetes: A Case Series. *Front Endocrinol (Lausanne)* 2019; **10**: 684 [PMID: 31749761 DOI: 10.3389/fendo.2019.00684]

21 **Maldonado MR**, Otiniano ME, Lee R, Rodriguez L, Balasubramanyam A. Characteristics of ketosis-prone diabetes in a multiethnic indigent community. *Ethn Dis* 2004; **14**: 243-9 [PMID: 15132210]

22 **Siddiqui RS**, Zirkiyeva M, Saliaj M. Onset of Ketosis-Prone Diabetes in the Setting of COVID-19 Infection. *Cureus* 2020; **12**: e10779 [PMID: 33154847 DOI: 10.7759/cureus.10779]

23 **Evans K**. Diabetic ketoacidosis: update on management. *Clin Med (Lond)* 2019; **19**: 396-398 [PMID: 31530688 DOI: 10.7861/clinmed.2019-0284]

24 **Maldonado M**, D’Amico S, Otiniano M, Balasubramanyam A, Rodriguez L, Cuevas E. Predictors of glycaemic control in indigent patients presenting with diabetic ketoacidosis. *Diabetes Obes Metab* 2005; **7**: 282-289 [PMID: 15811146 DOI: 10.1111/j.1463-1326.2004.00394.x]

25 **Maldonado MR**, Otiniano ME, Cheema F, Rodriguez L, Balasubramanyam A. Factors associated with insulin discontinuation in subjects with ketosis-prone diabetes but preserved beta-cell function. *Diabet Med* 2005; **22**: 1744-1750 [PMID: 16401322 DOI: 10.1111/j.1464-5491.2005.01724.x]

26 **Balasubramanyam A**, Garza G, Rodriguez L, Hampe CS, Gaur L, Lernmark A, Maldonado MR. Accuracy and predictive value of classification schemes for ketosis-prone diabetes. *Diabetes Care* 2006; **29**: 2575-2579 [PMID: 17130187 DOI: 10.2337/dc06-0749]

27 **Tuomilehto J**. Nonpharmacologic therapy and exercise in the prevention of type 2 diabetes. *Diabetes Care* 2009; **32 Suppl 2**: S189-S193 [PMID: 19875550 DOI: 10.2337/dc09-S308]

28 **Mauvais-Jarvis F**, Sobngwi E, Porcher R, Riveline JP, Kevorkian JP, Vaisse C, Charpentier G, Guillausseau PJ, Vexiau P, Gautier JF. Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistance. *Diabetes* 2004; **53**: 645-653 [PMID: 14988248 DOI: 10.2337/diabetes.53.3.645]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author’s Membership in Professional Societies:** American College of physician, No. 00084069; American College of Chest Physician, No. 157368; Society of Critical Care Medicine, No. 16809.

**Peer-review started:** July 20, 2022

**First decision:** August 7, 2022

**Article in press:** September 9, 2022

**Specialty type:** Critical care medicine

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Rwegerera GM, Botswana; Suravajhala PN, India **S-Editor:** Chen YL **L-Editor:** A **P-Editor:** Chen YL

**Table 1 Aß system for four ketosis-prone diabetes subgroups based on the presence/absence of autoantibodies and ß cell function**

|  |  |  |
| --- | --- | --- |
|  | **A+: Anti-GAD65 and IA-2 antibodies present in serum** | **A-: Anti-GAD65 and IA-2 antibodies not present in serum** |
| ß+: Fasting serum C-peptide concentration greater than or equal to 1 ng/mL (0.33 nmol/L) or a peak serum C-peptide response to glucagon greater than or equal to 1.5 ng/mL (0.5 nmol/L) | A+ß+: Autoantibodies present, beta cell function present | A-ß+: Autoantibodies absent, beta cell function present |
| ß-: Fasting serum C-peptide concentration is less than 1 ng/mL (0.33 nmol/L) or a peak serum C-peptide response to glucagon less than 1.5 ng/mL (0.5 nmol/L) | A+ß-: Autoantibodies present, beta cell function absent | A-ß-: Autoantibodies absent, beta cell function absent |

GAD65: Glutamic acid decarboxylase; IA-2: Anti-islet tyrosine phosphatase 2.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**